Rice Hall James & Associates, LLC holds a diversified book of 240 stocks worth $2.1B as of Q2 2026 (disclosed Aug 7, 2026, a ~38-day 13F lag). This quarter they opened Ascendis Pharma A/s and trimmed Ligand Pharmaceuticals. Their largest long position is Ligand Pharmaceuticals at 4% of the equity book.
Top-heavy: diversified book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
99% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
Other tracked managers holding the same core names as Rice Hall James & Associates, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 80 / 80 | $8.6B |
| Integrated Wealth Concepts LLC | 80 / 80 | $41.1M |
| BlackRock, Inc. | 79 / 80 | $33.8B |
| FMR LLC | 79 / 80 | $8.8B |
| MORGAN STANLEY | 79 / 80 | $5.2B |
| JPMORGAN CHASE & CO | 79 / 80 | $3.4B |
| GOLDMAN SACHS GROUP INC | 79 / 80 | $3.4B |
| UBS Group AG | 79 / 80 | $2.9B |
Ranked by the share of each fund's own book sitting in the names it shares with Rice Hall James & Associates, LLC: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Ligand Pharmaceuticals Inc COM NEW | $85.4M | 270.1K | 4.2% | ▼−4.8% Reduced · −14K sh | |
| 2 | Aci Worldwide Inc COM | $50.6M | 1.01M | 2.5% | ▲+0.3% Added · +3K sh | |
| 3 | Arlo Technologies Inc COM | $50.3M | 3.73M | 2.4% | ▲+2.0% Added · +73K sh | |
| 4 | Fabrinet SHS | $49.2M | 87.6K | 2.4% | ▼−17% Reduced · −18K sh | |
| 5 | Establishment Labs Hldgs Inc COM | $48.1M | 560.9K | 2.3% | ▲+2.2% Added · +12K sh | |
| 6 | Xpo Inc COM | $46.2M | 224.9K | 2.2% | ▲+0.3% Added · +579 sh | |
| 7 | Ziff Davis Inc COM | $43.0M | 821.5K | 2.1% | ▲+2.7% Added · +22K sh | |
| 8 | Shift4 PMTS Inc CL A | $42.5M | 874.5K | 2.1% | ▲+3.1% Added · +27K sh | |
| 9 | Kiniksa Pharmaceuticals Intl ORD SHS CL A | $40.0M | 624.9K | 1.9% | ▲+2.7% Added · +17K sh | |
| 10 | Ascendis Pharma A/s ORD SHS | $39.6M | 148.6K | 1.9% | ▲New New position | |
| 11 | Stride Inc COM | $37.9M | 439.0K | 1.8% | ▲+0.1% Added · +541 sh | |
| 12 | Prestige Consmr Healthcare I COM | $32.6M | 689.7K | 1.6% | ▲+32% Added · +168K sh | |
| 13 | Donnelley Finl Solutions Inc COM | $32.5M | 775.1K | 1.6% | ▼−0.6% Reduced · −5K sh | |
| 14 | Ituran Location And Control SHS | $29.0M | 475.5K | 1.4% | ▼−11% Reduced · −56K sh | |
| 15 | Medpace Hldgs Inc COM | $28.7M | 54.1K | 1.4% | ▲+0.2% Added · +133 sh | |
| 16 | Armstrong World Inds Inc New COM | $28.4M | 177.1K | 1.4% | ▲+0.2% Added · +290 sh | |
| 17 | Godaddy Inc CL A | $28.1M | 330.5K | 1.4% | ▲+3.4% Added · +11K sh | |
| 18 | Birkenstock Holding PLC COM SHS | $27.1M | 629.9K | 1.3% | ▲+6.7% Added · +40K sh | |
| 19 | Clear Secure Inc COM CL A | $27.0M | 485.0K | 1.3% | ▼−16% Reduced · −92K sh | |
| 20 | Ingevity Corp COM | $26.2M | 351.2K | 1.3% | ▲+1.8% Added · +6K sh | |
| 21 | Wex Inc COM | $25.2M | 178.6K | 1.2% | ▼−0.9% Reduced · −2K sh | |
| 22 | Sportradar Group AG CLASS A ORD SHS | $23.9M | 1.60M | 1.2% | ▲+1.0% Added · +16K sh | |
| 23 | Liquidity Svcs Inc COM | $23.8M | 608.5K | 1.2% | ▲+1.9% Added · +11K sh | |
| 24 | Federal Agric MTG Corp CL C | $23.5M | 118.1K | 1.1% | ▲+3.0% Added · +3K sh | |
| 25 | Biocryst Pharmaceuticals Inc COM | $23.3M | 2.33M | 1.1% | ▲+4.6% Added · +102K sh | |
| 26 | Upwork Inc COM | $23.2M | 2.78M | 1.1% | ▲+112% Added · +1.5M sh | |
| 27 | Genpact Limited SHS | $22.9M | 834.0K | 1.1% | ▲+18% Added · +130K sh | |
| 28 | Supernus Pharmaceuticals COM | $22.8M | 490.2K | 1.1% | ▲+2.7% Added · +13K sh | |
| 29 | Viridian Therapeutics Inc COM | $21.6M | 1.18M | 1.1% | ▲+31% Added · +277K sh | |
| 30 | Radware Ltd ORD | $21.0M | 680.9K | 1.0% | ▼−0.3% Reduced · −2K sh | |
| 31 | Alkermes PLC SHS | $20.5M | 390.9K | 1.0% | ▲+0.1% Added · +522 sh | |
| 32 | Nexxen Intl Ltd SHS NEW | $19.7M | 2.19M | 1.0% | ▲+3.3% Added · +69K sh | |
| 33 | Progress Software Corp COM | $19.1M | 570.3K | 0.9% | ▲+26% Added · +118K sh | |
| 34 | Quidelortho Corp COM | $18.6M | 1.06M | 0.9% | ▲+3.6% Added · +37K sh | |
| 35 | Lemaitre Vascular Inc COM | $18.2M | 189.9K | 0.9% | ▲+2.8% Added · +5K sh | |
| 36 | Euronet Worldwide Inc COM | $18.1M | 247.7K | 0.9% | ▲+2.4% Added · +6K sh | |
| 37 | LKQ Corp COM | $17.9M | 678.3K | 0.9% | ▼−1.0% Reduced · −7K sh | |
| 38 | Wix Com Ltd SHS | $17.4M | 382.6K | 0.8% | ▲+29% Added · +86K sh | |
| 39 | Neurocrine Biosciences Inc COM | $16.9M | 100.2K | 0.8% | ▲+0.2% Added · +205 sh | |
| 40 | Harrow Inc COM | $16.5M | 387.5K | 0.8% | ▲+5.3% Added · +19K sh | |
| 41 | Oshkosh Corp COM | $16.3M | 106.0K | 0.8% | ▲New New position | |
| 42 | Vail Resorts Inc COM | $15.9M | 117.1K | 0.8% | ▲+0.3% Added · +292 sh | |
| 43 | Acadia Pharmaceuticals Inc COM | $15.7M | 618.9K | 0.8% | ▲+0.2% Added · +1K sh | |
| 44 | Lci Inds COM | $15.1M | 142.7K | 0.7% | ▲+35% Added · +37K sh | |
| 45 | Varex Imaging Corp COM | $15.1M | 1.45M | 0.7% | ▲+13% Added · +171K sh | |
| 46 | Maximus Inc COM | $15.0M | 278.9K | 0.7% | ▲+25% Added · +56K sh | |
| 47 | Biomarin Pharmaceutical Inc COM | $14.2M | 248.2K | 0.7% | ▲+137% Added · +144K sh | |
| 48 | Taysha Gene Therapies Inc COM SHS | $13.6M | 1.99M | 0.7% | ▲+2.4% Added · +48K sh | |
| 49 | Bank Ozk Little Rock Ark COM | $13.5M | 259.4K | 0.7% | ▼−0.1% Reduced · −160 sh | |
| 50 | Mirum Pharmaceuticals Inc COM | $13.0M | 110.7K | 0.6% | ▼−25% Reduced · −36K sh |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/1230765/holdings"
Use Arkolith to show RICE HALL JAMES & ASSOCIATES, LLC's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Aug 7, 2026 | 240 | $2.1B | 13F-HR |
| Q1 2026 | Mar 31, 2026 | May 15, 2026 | 243 | $1.8B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 17, 2026 | 243 | $1.8B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Oct 16, 2025 | 248 | $1.8B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 11, 2025 | 247 | $1.9B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 1, 2025 | 248 | $1.7B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Jan 31, 2025 | 249 | $1.8B | 13F-HR |
| Q3 2024 | Sep 30, 2024 | Oct 28, 2024 | 250 | $1.8B | 13F-HR |
| Q2 2024 | Jun 30, 2024 | Aug 7, 2024 | 256 | $1.7B | 13F-HR |
| Q1 2024 | Mar 31, 2024 | Apr 23, 2024 | 257 | $1.8B | 13F-HR |
| Q4 2023 | Dec 31, 2023 | Feb 9, 2024 | 260 | $1.7B | 13F-HR |
| Q3 2023 | Sep 30, 2023 | Nov 2, 2023 | 260 | $1.6B | 13F-HR |
| Q2 2023 | Jun 30, 2023 | Jul 24, 2023 | 262 | $1.8B | 13F-HR |
| Q1 2023 | Mar 31, 2023 | May 12, 2023 | 262 | $1.8B | 13F-HR |
| Q4 2022 | Dec 31, 2022 | Jan 27, 2023 | 260 | $1.7B | 13F-HR |
| Q3 2022 | Sep 30, 2022 | Nov 1, 2022 | 265 | $1.7B | 13F-HR |
| Q2 2022 | Jun 30, 2022 | Aug 8, 2022 | 265 | $2.1B | 13F-HR |
| Q1 2022 | Mar 31, 2022 | May 26, 2022 | 306 | $2.5B | 13F-HR/A |
| Q4 2021 | Dec 31, 2021 | Feb 14, 2022 | 312 | $2.8B | 13F-HR |
| Q3 2021 | Sep 30, 2021 | Nov 9, 2021 | 309 | $2.7B | 13F-HR |
| Q2 2021 | Jun 30, 2021 | Jul 29, 2021 | 313 | $2.8B | 13F-HR |
| Q1 2021 | Mar 31, 2021 | May 14, 2021 | 315 | $3.1B | 13F-HR |
| Q4 2020 | Dec 31, 2020 | Feb 16, 2021 | 300 | $2.8B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.